Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices NYT | Top Stories By: Rebecca Robbins 23 October 2025 at 17:00 In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. © Audra Melton for The New York TimesEnbrel, a once-a-week injection used to treat a variety of autoimmune conditions, first arrived on the market nearly 30 years ago.
Login
